Did Trump Get Special Access to Retatrutide?

Amid growing speculation about President Donald Trump potentially receiving early access to retatrutide, an experimental weight-loss drug from Eli Lilly, questions have emerged about preferential treatment for high-profile individuals. This comes as the drug is highly anticipated by many seeking effective weight management solutions, highlighting concerns about equity in medical access. The rumors add to the broader conversation about the influence of power and wealth in securing benefits that may not yet be available to the general public.